Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Current Assets (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Current Assets for 13 consecutive years, with $206.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 39.49% to $206.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $206.7 million through Dec 2025, down 39.49% year-over-year, with the annual reading at $206.7 million for FY2025, 39.49% down from the prior year.
  • Current Assets hit $206.7 million in Q4 2025 for Coherus Oncology, down from $461.0 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $673.0 million in Q3 2021 to a low of $206.7 million in Q4 2025.
  • Historically, Current Assets has averaged $460.8 million across 5 years, with a median of $447.5 million in 2022.
  • Biggest five-year swings in Current Assets: soared 98.62% in 2024 and later tumbled 50.57% in 2025.
  • Year by year, Current Assets stood at $602.3 million in 2021, then crashed by 36.71% to $381.2 million in 2022, then grew by 24.76% to $475.6 million in 2023, then fell by 28.18% to $341.6 million in 2024, then plummeted by 39.49% to $206.7 million in 2025.
  • Business Quant data shows Current Assets for CHRS at $206.7 million in Q4 2025, $461.0 million in Q3 2025, and $380.2 million in Q2 2025.